Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice following a Single Intranasal Dose by Ming Zhang et al.
ORIGINAL RESEARCH
published: 07 February 2017
doi: 10.3389/fcimb.2017.00034
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 February 2017 | Volume 7 | Article 34
Edited by:
Luka Cicin-Sain,
Helmholtz Zentrum für
Infektionsforschung GmbH, Germany
Reviewed by:
Subramanian Dhandayuthapani,
Texas Tech University Health Sciences
Center, USA
Brian Weinrick,
Albert Einstein College of Medicine,
USA
*Correspondence:
Chunsheng Dong
chunshengdong@suda.edu.cn
Sidong Xiong
sdxiongfd@126.com
Received: 14 December 2016
Accepted: 24 January 2017
Published: 07 February 2017
Citation:
Zhang M, Dong C and Xiong S (2017)
Vesicular Stomatitis Virus-Vectored
Multi-Antigen Tuberculosis Vaccine
Limits Bacterial Proliferation in Mice
following a Single Intranasal Dose.
Front. Cell. Infect. Microbiol. 7:34.
doi: 10.3389/fcimb.2017.00034
Vesicular Stomatitis Virus-Vectored
Multi-Antigen Tuberculosis Vaccine
Limits Bacterial Proliferation in Mice
following a Single Intranasal Dose
Ming Zhang, Chunsheng Dong* and Sidong Xiong*
Jiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences, Soochow University, Suzhou,
China
Tuberculosis (TB) remains a serious health problem worldwide, and an urgent need
exists to improve or replace the available vaccine, Mycobacterium bovis bacillus
Calmette-Guérin (BCG). Most vaccination protocols adapt two or three doses to induce
long-term lasting immunity. Our previous study showed that the naked DNA encoding
the triple-antigen fusion TFP846 (Rv3615c-Mtb10.4-Rv2660c) induced robust T cellular
immune responses accompanying four inoculations against mycobacteria infection.
However, a number of compliance issues exist in some areas lacking the appropriate
medical infrastructure with multiple administrations. In this study, a novel vesicular
stomatitis virus expressing TFP846 (VSV-846) was developed and the immune responses
elicited by VSV-846 were evaluated. We observed that intranasal delivery of VSV-846
induced a potent antigen-specific T cell response following a single dose and VSV-846
efficiently controlled bacterial growth to levels ∼10-fold lower than that observed in the
mock group 6 weeks post-infection in BCG-infected mice. Importantly, mice immunized
with VSV-846 provided long-term protection against mycobacteria infection compared
with those receiving p846 or BCG immunization. Increased memory T cells were also
observed in the spleens of VSV-846-vaccinated mice, which could be a potential
mechanism associated with long-term protective immune response. These findings
supported the use of VSV as an antigen delivery vector with the potential for TB vaccine
development.
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INTRODUCTION
Tuberculosis (TB) remains a serious health problem worldwide. One-third of the population has
been infected with Mycobacterium tuberculosis (M.tb), and people infected with dormant M.tb
are diagnosed as having non-clinical TB or latent TB infection, with ∼5–10% of these people
developing TB disease in their lives(WHO, 2004). Furthermore, latently infected individuals have
an ∼10%/year risk of developing active TB disease in HIV-infected persons if they do not receive
antiretroviral therapy (Cohn, 2000). Therefore, successful vaccines against M.tb infection are
needed.
Mycobacterium bovis bacillus Calmette-Guérin (BCG), the only available vaccine against TB, has
failed to control adult TB and the establishment of latent persistent (TB) infection (Brewer, 2000;
Glyn Hewinson, 2005). According to the previous studies, T cell-mediated immunity characterized
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by the secretion of IFN-γ and other cytokines plays an important
role for the protection against M.tb infection (Cooper, 2009).
Vaccine-specific T cell memory can also confer protection upon
secondary challenge by a qualitatively different and quantitatively
enhanced response (Henao-Tamayo et al., 2014).
We previously showed that a novel triple-antigen fusion DNA
vaccine p846, engineered with three well-defined mycobacterial
antigens [Rv3615c (Millington et al., 2011), Mtb10.4 (Hogarth
et al., 2006), and Rv2660c (Betts et al., 2002)], induced robust T
cell-mediated immune responses following four immunizations
(Kong et al., 2014). Considering that there are many issues
in some areas lacking the medical infrastructure to support
multiple injections (Fachado et al., 2003), vaccination with a
needle-free single dose should be considered as an important
goal for vaccine development. Vesicular stomatitis virus (VSV),
a negative-stranded RNA virus, has been proved to be a
favorite viral vector for delivery of foreign vaccine antigens
(Rose et al., 2001; Haglund et al., 2002; Clarke et al., 2007;
Braxton et al., 2010). VSV has three major advantages as a
potential delivery platform against TB. First, we and other
groups demonstrated that VSV can be vaccinated through
mucosa (Tan et al., 2005; Wu et al., 2014). It is believed that
it is superior to elicit protective immune responses against
infectious diseases at the site of infection (Davis, 2001). Second,
with the help of the VSV reverse genetic system, additional
genes can be easily inserted into the viral genome, and the
recombinant VSV (rVSV) expressing foreign antigens can be
grown to high titers in mammalian cell lines(Goonetilleke et al.,
2003). Third, rVSV could stimulate potent humoral and cell-
mediated immune responses in a needle-free single dose in
animal models (Johnson et al., 1997; Faber et al., 2005; Cobleigh
et al., 2010). Additionally, the prevalence of anti-VSV antibodies
in the general population is extremely low. Therefore, few
people carry pre-existing antibodies to counteract the VSV-based
vaccines (Lichty et al., 2004). Previously, a VSV based TB vaccine
VSVAg85A expressing the highly immunogenic antigen Ag85A
was shown to be protective upon pulmonary M.tb challenge
when administrated to mice intranasally (Roediger et al., 2008).
However, this protection manifested at an early time-point as
detected 2 weeks following immunization and was not sustained.
Here, we developed a VSV-based vaccine VSV-846 expressing
a well-defined triple-antigen fusion gene that was effective against
the mycobacterium infection described in our previous report
(Kong et al., 2014). Our results indicated that vaccination
with VSV-846 elicited a remarkable T cell-mediated immune
response and provides effective long-term protection following
BCG challenge within a needle-free single dose. These findings
may also provide insight for further M.tb-vaccine development.
MATERIALS AND METHODS
Immunization Protocols
Female BALB/c mice, 6–8 weeks old, were purchased from
the experimental animal center of the Chinese Academy of
Sciences and maintained in pathogen-free conditions. All
animal experiments were performed in accordance with the
laboratory animals’ guidelines of the Laboratory Animal Ethical
Commission of Soochow University (SYXK2014-0030).
Mice were lightly anesthetized with 30% isoflurane (Baxter)
diluted in propylene glycol prior to all immunizations. Single
intranasal inoculations of 106 PFU were administered in a
25 µl volume for VSV-846. For BCG immunization, mice
received a single dose of 1 × 107 colony-forming units (CFU)
BCG subcutaneously. For plasmid immunization, mice were
intramuscularly injected with 50 µg p846 for 4 times biweekly.
(1) For VSV-846 induced immune response and protection
detection, each group consisted of twelve mice. Six mice per
group were sacrificed 2 weeks after the final DNA vaccination
for IFN-γ release assay, Lymphocyte proliferation assay and
cytotoxic T lymphocyte measument. The other six mice per
group were challenged with BCG 6 weeks after the final DNA
vaccination and sacrificed 6 weeks after the challenge for bacterial
load detection. (2) For VSV-846 induced long-term protection
detection, each group consisted of eighteen mice. Six mice per
group were sacrificed 6, 12, or 24 weeks after BCG challenge for
the bacterial load detection and evaluation of pathology. (3) For
VSV-846 inducedmemory T cells detection, each group consisted
of six mice. These mice were sacrificed 24 weeks after the final
DNA vaccination for memory T cells detection.
Bacterial Strains and Culture Conditions
Escherichia coli strain DH5α was grown in a Luria-Bertani
medium for cloning. M. bovis BCG (Denmark strain 1331) was
provided by the Center for Disease Control of Suzhou and was
cultivated in a Middlebrook 7H9 medium or enumerated on
7H11 agar supplemented with 10% oleic acid-albumin-dextrose-
catalase, 0.5% glycerol, and 0.05% Tween 80. Inactivated M.tb
H37Rv strain was provided by the Fifth People’s Hospital of
Suzhou.
Generation of VSV-Based Vaccine, VSV-846
The fusion gene-encoding Rv3615c, Mtb10.4, and Rv2660c was
amplified by PCR as previously described (Kong et al., 2014).
The PCR product was cleaved with XhoI and NheI and cloned
into the fifth position of the pVSV-XN2 plasmid (Cobleigh
et al., 2010), generating pVSV-XN2-846. The recombinant VSV-
846 virus was generated by the following procedure: In brief,
baby hamster kidney cells BHK-21 (ATCC number:CCL-10)
grown to 60% confluence were infected with recombinant
vaccinia virus expressing T7 RNA polymerase (Fuerst et al.,
1986) and incubated for 1 h in serum-free Dulbecco’s modified
Eagle’s medium (DMEM). Vaccinia virus-infected cells were
then co-transfected with the plasmids pVSV-XN2-846 and
the other plasmids for the expression of VSV N, P, and L
(Ritz et al., 2012). Supernatants were collected 48 h post
transfection, filtered through a 0.2µm pore filter to remove
vaccinia virus, and passaged onto fresh BHK-21 cells. The
mediumwas collected immediately and filtered through a 0.2µm
pore filter after cytopathic effects were observed 2 days later.
Recombinant VSV was then plaque purified and expanded. The
titer was determined, and the VSV-846 was stored at −80◦C
until use.
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Western Blot
BHK-21 cells were infected with VSV-846 and harvested 6 h
post-infection. Cells were washed with phosphate-buffered saline
(PBS) and lysed with 2 × SDS sample buffer. Proteins were
separated on a 10% SDS gel, transferred to a nitrocellulose
membrane, probed with anti-flag antibody (Sigma 1:2000), and
detected with a secondary antibody (Southern Biotech 1:5000)
using chemiluminescence.
IFN-γ Release Assay
Two weeks after last immunization, spleen cells isolated from
vaccine-immunized mice were plated at 5 × 106 cells/well in 24-
well plates. These cells were stimulated with TFP846 protein (10
µg/ml) as previously described (Kong et al., 2014) at 37◦C for
72 h. The concentrations of IFN-γ in the culture supernatant
were measured with an ELISA kit (eBioscience) according to the
manufacturer’s procedure.
Lymphocyte Proliferation Assay
The proliferation of splenocytes from immunized mice was
measured 2 weeks after the last immunization. Viable splenocytes
were adjusted to a concentration of 5× 106 cells/ml and added to
96-well flat-bottomed plates at 5× 105 cells/well with 10µg/ml of
TFP846 protein. A BrdU-labeling reagent (Roche) was added to
each well at a ratio of 1:1000. The culture plates were maintained
in the same conditions for another 24 h and then incubated
with anti-BrdU peroxidase. The absorption value at 370 nm was
measured. Each sample was analyzed in triplicate.
Measurement of Cytotoxic T Lymphocyte
Two weeks after the final DNA immunization, splenocytes
were isolated and stimulated in vitro with 10 µg/mL of the
recombinant TFP846 proteins in the vaccinated mice at 37◦C,
5% CO2. Mouse myeloma cell line SP2/0 cells from Cell
bank of Chinese Academy of Science were pulsed with the
inactivated M. tb H37Rv for 24 h as target cells. A nonradioactive
cytotoxic T lymphocyte (CTL) assay was performed with a lactate
dehydrogenase (LDH) cytotoxicity detection kit (Roche). The
effector cells were titrated in U-bottom 96-well plates at effector–
target cell ratios of 50:1, 25:1, and 12.5:1; 1 × 104 target cells
were then added. After incubation at 37◦C for 72 h, 100 uL
of cell supernatant per well was removed and transferred into
corresponding wells of the 96-well plate. A reaction mixture
(100 uL) was added to each well, which was incubated at room
temperature for 30 min. The absorbance value at 492 nm was
measured. The percentage cytotoxicity of CTL was calculated as
follows:
Cytotoxicity (%) = [(effector and target cell mixture
− effector cell control)− low control]/
(high control− low control)× 100%;
According to the protocol, high control was the maximum
releasable LDH activity in the cells (50 uL cell culture medium,
50 uL untreated cells and 5 uL lysis buffer). Low control was the
spontaneous LDH activity released from the untreated normal
cells (50 uL cell culture medium, 50 uL untreated cells).
Mice Challenage and Colony-Forming
Units Assay
Six weeks after final DNA vaccination, the immunized mice were
intranasally challenged with 1 × 107 CFU of BCG as previouly
described (Kong et al., 2014; Song et al., 2015). The bacteria load
in the spleens and lungs at indicated time points post-challenge
was counted according to the colony-forming units of serial
dilutions of tissue homogenates on aMiddlebrook 7H11medium
in triplicate.
Histopathological Analysis and
Inflammation Severity Evaluation
For histopathological analysis, lungs from the immunized mice
(n = 6 per group) were collected 24 weeks post BCG challenge.
The tissues were sectioned and stained with hematoxylin and
eosin. Five sections were made from each mouse in one
experiment. Two sections from each mouse were then randomly
selected and total twelve sections of each groupwere evaluated for
inflammation scoring by two independent investigators in one
experiment. Inflammation score was assessed as the percentage
of inflammation area compared with the overall size of the tissue
section, with the aid of a microscope eyepiece grid as previously
reported (Fairweather et al., 2005; Liu et al., 2014).
Flow Cytometry
Twenty four weeks post final DNA immunization, the
splenocytes were isolated from the immunized mice (n = 6
per group). CD4+ memory cells were stained with PerCP-
Cy5.5-anti-mouse CD4 (Biolegend), FITC-anti-mouse CD44
(Biolegend), PE-anti-mouse CD62L (Biolegend), and APC-Cy7-
anti-mouse CD25 (Biolegend). CD8+ memory cells were stained
with PerCP-anti-mouse CD8 (Biolegend), PE-anti-mouse CD62L
(Biolegend), and Pacific blue-anti-mouse CD45R (Biolegend)
antibodies. The stained cells were fixed with Cytofix/Cytoperm
Buffer
TM
(Becton Dickson) and then analyzed with a FACS
Canto II flow cytometer with FACSDiva software.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism. Data
were from three separate experiments and given as mean and
standard deviation. The data were statistically analyzed by two-
tailed independent Student’s t-test through SPSS 12.0. The level
of statistical significance was set to P < 0.05.
RESULTS
Generation and Identification of VSV-846
Carrying Mycobacteria Triple-Antigen
Fusion
To generate VSV-based vaccine, the triple-antigen fusion TFP846
(Rv3615c-Mtb10.4-Rv2660c) gene in the p846 plasmid was
amplified (Kong et al., 2014), and then cloned into the VSV
genome at the fifth position of the VSV antigenome (Figure 1A).
The rVSV in cell culture supernatant was harvested 48 h post
transfection for purification. BHK-21 cells infected with rVSVs
appeared cytopathic 6 h post-infection (Figure 1B). Expression
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FIGURE 1 | Generation and identification of VSV-846 vaccine. (A) The schematic of pVSV-XN2-846 plasmid. The triple-antigen fusion TFP846
(Rv3615c-Mtb10.4-Rv2660c) was amplified from p846 plasmid, and the triple-antigen fusion gene was then cloned into the fifth position of the pVSV-XN2 plasmid
after cleavage with XhoI and NheI. (B) The microscope images of BHK-21 cells infected with VSV-846 or non-infected mock control 6 h post-infection (200×). (C) The
triple-antigen fusion TFP846 was expressed in VSV-846 infected cells. The blot was probed with anti-flag antibody. Control: Normal cells without infection.
of the triple-antigen gene was confirmed by anti-flag antibody
(Figure 1C). These results indicated successfully generation of
a VSV-based vaccine VSV-846 expressing M.tb triple-antigen
fusion TFP846.
Evaluation of VSV-846 Induced Cellular
Responses and Protection
Given the important role of cellular responses against
mycobacteria infection, we evaluated the cellular responses
induced by VSV-846 2 weeks after final DNA immunization
(Figure 2). An IFN-γ release assay was performed to determine
whether the VSV-846 vaccine was capable of inducing high levels
of antigen specific IFN-γ+ T cells. Our results revealed that the
level of IFN-γ secreted by VSV-846 immunized mouse spleen
cells was higher compared with those from p846 immunized
mouse spleens cells following incubation with TFP846 protein
(Figure 3A, ∗P < 0.05), and were similar to the level of IFN-γ
secreted by BCG immunized mouse spleen cells. Significantly
elevated antigen specific T cell proliferation was also observed
in VSV-846 immunized mice in response to TFP846 protein,
as compared with those of the mice immunized with p846
(Figure 3B, ∗p < 0.05). Specific cytotoxic T lymphocyte (CTL)
activity was assessed by using SP2/0 cells as target cells. The
strongest antigen-specific cytotoxicity response was detected in
VSV-846 immunized at an E:T ratio of 50:1 (Figure 3C, ∗p <
0.05).
To investigate the degree of protection, immunized mice
were intranasally challenged with 107 colony-forming unit (CFU)
BCG, and the bacterial loads in the lungs were determined 6
weeks post-infection. We observed that VSV-846 vaccination
efficiently controlled bacterial growth to levels— ∼10-fold lower
than those observed in the mock group and 2.2-fold lower than
those observed in the p846 group (Figure 3D, ∗p < 0.05 and ∗∗∗p
< 0.001). However, the bacterial load in VSV-846 immunized
mice was not significantly different from that observed in BCG
immunizedmice. These results showed that VSV-846 vaccination
induced robust specific T cell immune response and protected
mice from mycobacteria infection 12 weeks post-vaccination.
VSV-846 Immunization Elicited Long-Term
Protection
To determine whether VSV-846 vaccination induced long-term
immune responses, groups of BALB/c mice were immunized
and challenged. The bacterial loads in mouse lungs were
evaluated over time. Consistent with results shown in Figure 3,
6 weeks post-bacterial challenge, mice were protected by VSV-
846 vaccination. This method resulted in 1.47 log reduction of
lung CFUs as compared with those observed in the mock control,
although this finding was not significantly different from that
of the BCG group. Interestingly, investigation of time points
at 12 and 24 weeks post-challenge revealed that bacterial loads
in the VSV-846-immunized group were significantly lower than
those of the BCG group (Figure 4A, ∗∗p < 0.01 and ∗∗∗p <
0.001), suggesting that VSV-846 vaccination may induce better
long-term protection against bacterial infection. Twenty four
weeks after challenge, the pathology of lung tissues was analyzed.
Sections from the normal mice were examined, revealing severe
interstitial pneumonia, inflammation, and diffuse granuloma-
like responses following BCG infection. However, VSV-846-
immunized mice showed much less inflammation and intact
alveolar morphology as compared with mice vaccinated with
p846 or BCG, indicating that VSV-846 vaccination alleviated lung
injury following BCG challenge (Figure 4B).
VSV-846 Increased the Magnitude of
Memory CD4 + and CD8 +T Cells
Memory T cells are capable of responding more rapidly and
mediating faster viral clearance upon re-exposure to antigen. A
long-term immune response based on the presence of memory
(CD44+ CD62LLow CD25−) CD4+ T and (CD44+ CD62LLow
CD45R−) CD8+ Tcells is examined to determine protection
from mycobacterium infection (Sondel et al., 2003). Mice were
immunized with VSV-846, and 24 weeks after final DNA
vaccination, splenocytes were isolated for quantifying memory
T cell response. CD25− T cells or CD45R− T cells were gated
from CD4+ or CD8+ T cells by flow cytometry, respectively. The
long-term memory T cells were then characterized by CD44+
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FIGURE 2 | Timeline of animal vaccination, challenge and detection. Group of BALB/c mice was administered in a 25 µl volume for VSV-846 (single intranasal
inoculations of 106 PFU). Separately, mice immunized with 50 µg of p846 plasmid DNA administered intramuscularly or 106 CFU BCG injected subcutaneously
served as control groups. The immune response detection, BCG challenge, bacterial load, and evaluation of pathology were applied as indicated in the time points.
FIGURE 3 | Cellular responses and protection induced by VSV-846. (A) Antigen-specific IFN-γ released from splenocytes purified from VSV-846-immunized
BALB/c mice after in vitro stimulation with recombinant TFP846 2 weeks post immunization. (B) The specific T cells proliferation in spleen as measured by BrdU assay
2 weeks post immunization. (C) The specific cytotoxicity response was detected in the splenic tissue derived from mice immunized with VSV-846 at an E: T ratio of
50:1∼12.5:1. For one experiment, each group consisted of six mice. Results are represented as the mean ± SD of three separate experiments. The error bar
represents the standard deviation of three means in repeated experiments. *p< 0.05, **p < 0.01. (D) Bacterial numbers in one experiment (n = 6 per group) in the
lungs of BALB/c mice subjected to various vaccinations challenged with Mycobacterium bovis BCG 6 weeks post vaccination. *p < 0.05, ***p < 0.001.
and CD62LLow. As shown in Figure 5, the percentage of both
CD4+ (15.85%) and CD8+ (8.69%) memory T cells was higher in
the VSV-846 group as compared with that observed in the BCG
group (Figures 4A,B, ∗p < 0.05 and ∗∗∗p < 0.001), indicating
that VSV-846 immunization was capable of providing sustained
cellular immunity.
DISCUSSION
In recent years, immunization with live replication-competent
VSV vaccines has been shown to be an effective method of
vaccine development (Rose et al., 2001; Haglund et al., 2002;
Clarke et al., 2007; Braxton et al., 2010). VSV vectors shared
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FIGURE 4 | Long-term immunity and protective efficacy of VSV-846. (A) Groups of mice were immunized and challenged with Mycobacterium bovis BCG. The
bacterial loads in mouse lungs were determined over a period of 24 weeks post-challenge. For one experiment, each group consisted of six mice. Results are
represented as the mean ± SD of three separate experiments. The error bar represents the standard deviation of three means in repeated experiments. **p < 0.01,
***p < 0.001. (B) Pathology of H&E-stained lung tissues (left panel, scale bar: 100µm). and inflammation score (right panel) 24 weeks post-challenge are presented.
Pictures shown are representative images of one experiment. Data of inflammation scores are represented as the mean ± SD of three separate experiments. The error
bar represents the standard deviation of three means in repeated experiments. **p < 0.01.
certain advantages for use in vaccine delivery. Specifically, they
can induce robust humoral and cell-mediated Th1 immunity
following a single dose in the absence of an additional adjuvant
(Publicover et al., 2005). So far, traditional vaccinations require
repeated doses to induce long-lasting immunity and specific
adjuvant are often needed. For example, the two-dose HeVsG
vaccine requires the action of two adjuvants, all hydrogels, and
the CpG oligo deoxynucleotide (Bossart et al., 2012) to generate
a Th1 immune response. However, hydrogels alone typically
induce a Th2 response that is not appropriate against viral
infections (Coffman et al., 2010; Steinhagen et al., 2011).
We previously reported that a naked DNA plasmid encoding
TFP846 protein inoculated four times elicited a robust T cell-
mediated immune response (Kong et al., 2014). In this study, we
showed that protection along with long-term immune response
against mycobacterial infection in mice was effectively achieved
by intranasal immunization with a single-dose of VSV-based
vaccine, VSV-846.
Vaccine induced CD4+ T cells are known to secrete
phagocyte-activating type 1 cytokines like IFN-γ and TNF-
α, which contribute to intracellular antimicrobial defense by
activating macrophages (Kerksiek and Pamer, 1999; Schroder
et al., 2004). Recent studies suggest that both CD4+ T cells
and IFN-γ play critical roles in combating bacterial infections
(Malley et al., 2005; Pilione and Harvill, 2006). The triple
antigen fusion TFP846 contains three M.tb antigens: Rv3615c
(Boesen et al., 1995), M.tb10.4 (Skjøt et al., 2000) and Rv2660c
(Betts et al., 2002). Both Rv3615c and M.tb10.4 cover high
density of T cell epitopes that promote strong T cell immune
response, including functional T cell subsets secreting both
IFN-γ and IL-2 (Millington et al., 2011). Rv2660c is stably
expressed in the early and late stages of M.tb infection, and
significantly enhances protective immunity characterized by a
high proportion of multifunctional CD4+ T cells against M.tb
infection in mice and cynomolgus macaques (Aagaard et al.,
2011; Lin et al., 2012). Here, a strong cellular immune response
was induced with a single dose of VSV-846, as shown by increased
IFN-γ release, lymphocyte proliferation, and T cell cytotoxicity
(Figures 3A–C).
Although similar bacterial loads were measured in VSV-846
and BCG immunized mice 6 weeks post-challenge, these became
significantly different at long-term intervals, including 12 and
24 weeks post-challenge. This result differed from that reported
by Roediger (Roediger et al., 2008), where VSVAg85A only
conferred transient protecion from pulmonary M.tb challenge
following single respiratory mucosal immunization. Considering
that the same viral vector systemwas used, possible explanation is
that the triple-antigen fusion TFP846 is more robust at inducing
anti-TB immune responses as compared with using single M.tb
antigens.
Memory T cells contribute to host defenses during a wide
range of viral and intracellular bacterial infections (Harty et al.,
2000). Both the effector memory T cells and the sustainable, high
proliferative capacity of central memory T cells are important for
a potentially successful TB vaccine (Andersen and Woodworth,
2014; Nunes-Alves et al., 2014). CD62L is a lymph node
homing receptor that is down-regulated upon CTL activation
(Ottenhoff and Kaufmann, 2012). CD44 is a surface protein
required for lymphocyte extravasation to inflammatory sites
and its up-regulation represents a marker for memory T cells
(Harty et al., 2000). In this study, we observed that a large
population of CD44+ and CD62LLow memory T cells from
isolated splenocytes 24 weeks post-vaccination. Although we
observed much higher percentage of CD44+ and CD62LLow
memory T cells following VSV-846 immunization relative to
those of BCG-immunized mice, we were unable to determine
whether these memory T cells were generated from VSV-846
induction without antigen-specific tetramer staining. Previously,
a VSV-based vaccine reportedly induced poly functional T cells
proliferation that secrete activating cytokines, such as IL-2, IFN-γ
and TNF-α, and contribute to antiviral defense (Wu et al., 2014).
However, no study has shown the capability of vaccine-elicited
cells secreting multiple cytokines during infection to develop
into long-lived memory T cells exhibiting enhanced capability to
control infection, as evidenced by the clinical failure of MVA85A
(Ottenhoff and Kaufmann, 2012).
In conclusion, our results indicate that the VSV-based TB
vaccine VSV-846 elicited robust cellular immune responses, as
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FIGURE 5 | Memory T cells immune responses induced by VSV-846 24-weeks post final DNA immunization, the splenocytes of immunized mice (n = 6
per group) were isolated and the memory T cells were analyzed by flow cytometry. VSV-846 immunization particularly increased the frequency of memory (A)
CD4+ and (B) CD8+ T cells compared with p846 or BCG immunization, suggesting that VSV-846 immunization may provide a more effective protection by inducing
these T cells in the late stages of infection. The scatter plots are shown from the splenocytes of a single mouse. For one experiment, each group consisted of six mice.
Results are represented as the mean ± SD of three separate experiments. The error bar represents the standard deviation of three means in repeated experiments. *p
< 0.05, ***p < 0.001.
well as memory T cell responses, and it protects vaccinated mice
against BCG infection over long-term periods of time following
a needle-free single dose. These findings showed that use of VSV
as an antigen-delivery vector is a potentially successful option for
TB-vaccine development.
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